Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando L Pagan

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The American Journal of Managed Care|October 9, 2012
Improving outcomes through early diagnosis of Parkinson's diseaseFernando L Pagan
Parkinsonism & Related Disorders|March 13, 2012
A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin AFernando L Pagan, Andrew Harrison
Patient Preference and Adherence|June 18, 2015
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type AReversa R Mills, Fernando L Pagan
Neurology|April 23, 2003
Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopyFernando L Pagan, John A Butman, James M Dambrosia, et al.
Clinical Parkinsonism & Related Disorders|August 29, 2022
Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?Stuart H Isaacson, Fernando L Pagan, Mark F Lew, et al.
Neurology and Therapy|May 23, 2023
Clinical Use of On-Demand Therapies for Patients with Parkinson's Disease and OFF PeriodsRajesh Pahwa, Fernando L Pagan, Daniel E Kremens, et al.
CNS Drugs|April 8, 2024
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease PsychosisFernando L Pagan, Paul E Schulz, Yasar Torres-Yaghi, et al.
Parkinsonism & Related Disorders|September 12, 2025
Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with Lewy bodiesFernando L Pagan, Yasar Torres-Yaghi, Michaeline L Hebron, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 20, 2020
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's DiseaseFernando L Pagan, Barbara Wilmarth, Yasar Torres-Yaghi, et al.
Neuropsychologia|September 24, 2020
Can sex influence the neurocognition of language? Evidence from Parkinson's diseaseJana Reifegerste, Ivy V Estabrooke, Lauren E Russell, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The American Journal of Managed Care|October 9, 2012
Improving outcomes through early diagnosis of Parkinson's diseaseFernando L Pagan
Parkinsonism & Related Disorders|March 13, 2012
A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin AFernando L Pagan, Andrew Harrison
Patient Preference and Adherence|June 18, 2015
Patient considerations in the treatment of cervical dystonia: focus on botulinum toxin type AReversa R Mills, Fernando L Pagan
Neurology|April 23, 2003
Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopyFernando L Pagan, John A Butman, James M Dambrosia, et al.
Clinical Parkinsonism & Related Disorders|August 29, 2022
Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?Stuart H Isaacson, Fernando L Pagan, Mark F Lew, et al.
Neurology and Therapy|May 23, 2023
Clinical Use of On-Demand Therapies for Patients with Parkinson's Disease and OFF PeriodsRajesh Pahwa, Fernando L Pagan, Daniel E Kremens, et al.
CNS Drugs|April 8, 2024
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson's Disease PsychosisFernando L Pagan, Paul E Schulz, Yasar Torres-Yaghi, et al.
Parkinsonism & Related Disorders|September 12, 2025
Safety, tolerability and potential biomarkers of vodobatinib in patients with dementia with Lewy bodiesFernando L Pagan, Yasar Torres-Yaghi, Michaeline L Hebron, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 20, 2020
Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's DiseaseFernando L Pagan, Barbara Wilmarth, Yasar Torres-Yaghi, et al.
Neuropsychologia|September 24, 2020
Can sex influence the neurocognition of language? Evidence from Parkinson's diseaseJana Reifegerste, Ivy V Estabrooke, Lauren E Russell, et al.
Pageof 3